Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis
Issued Date
2025-01-01
Resource Type
ISSN
09024441
eISSN
16000609
Scopus ID
2-s2.0-105000442803
Journal Title
European Journal of Haematology
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Haematology (2025)
Suggested Citation
Vittayawacharin P., Lee B.J., E'leimat G., Cao Y., Reid J., Gamayo A., Rezk S., Brem E.A., Lee L.X., Kongtim P., Ciurea S.O. Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis. European Journal of Haematology (2025). doi:10.1111/ejh.14412 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/108497
Title
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Data on bone marrow (BM) findings in secondary hemophagocytic lymphohistiocytosis (sHLH) and their association with overall survival (OS) are limited. Objectives: This study aimed to develop a prognostic model incorporating BM findings and clinico-laboratory factors affecting OS. Methods: We retrospectively evaluated 50 adults with sHLH and developed a clinicopathological prognostic model based on survival-associated factors. Results: Most patients demonstrated normocellular BM (46.3%) and mild hemophagocytic activity (44.2%). Factors associated with survival in multivariable analyses (MVA) were age above 70 years (hazard ratio [HR] 3.89, p = 0.016), infection-related (HR 4.62, p = 0.006), hemoglobin < 7 g/dL (HR 5.21, p < 0.001), and hypocellular marrow (HR 3.07, p = 0.04). A clinicopathological HLH risk model assigned 1 point to each MVA-identified survival factor, categorizing patients into low- (score 0–1), intermediate- (score 2–3), and high-risk (score 4) groups. The 6-month OS from bootstrapping internal validation among the low-, intermediate-, and high-risk groups were 84.2%, 55.6% (p < 0.001) and 7.7% (p < 0.001), respectively. The area under the receiver operating characteristic curve (AuROC) was 0.87. Conclusions: This model stratified sHLH patients into three risk groups with distinct survival outcomes, potentially guiding future therapy.